FY2027 EPS Estimate for Cardiff Oncology Boosted by Analyst

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities research analysts at Zacks Research boosted their FY2027 earnings per share (EPS) estimates for Cardiff Oncology in a research report issued to clients and investors on Tuesday, February 3rd. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.74) for the year, up from their previous forecast of ($0.77). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.12 million.

A number of other research firms also recently weighed in on CRDF. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Noble Financial assumed coverage on shares of Cardiff Oncology in a report on Monday, January 5th. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.13.

Cardiff Oncology Stock Up 8.1%

Shares of CRDF opened at $1.60 on Thursday. The business’s 50 day moving average is $2.52 and its two-hundred day moving average is $2.39. Cardiff Oncology has a 52-week low of $1.48 and a 52-week high of $4.99. The firm has a market cap of $107.78 million, a price-to-earnings ratio of -2.03 and a beta of 1.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after buying an additional 4,232 shares during the last quarter. SteelPeak Wealth LLC raised its stake in Cardiff Oncology by 23.2% during the 2nd quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock valued at $72,000 after acquiring an additional 4,300 shares in the last quarter. Invesco Ltd. boosted its position in Cardiff Oncology by 24.9% during the 2nd quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after acquiring an additional 4,749 shares during the period. AlphaCore Capital LLC boosted its position in Cardiff Oncology by 8.2% during the 3rd quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock worth $226,000 after acquiring an additional 8,351 shares during the period. Finally, Raymond James Financial Inc. grew its stake in shares of Cardiff Oncology by 70.1% in the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock worth $49,000 after purchasing an additional 9,740 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.